AmyPore
AmyPore is a biotechnology company founded in 2018 that designs and develops therapeutic peptides to create treatments for neurodegenerative diseases, specifically Alzheimer's and Parkinson's diseases. Their lead product, AmyP53, is a chimeric peptide developed through an innovative strategy combining molecular modeling and artificial intelligence applied to molecular neuroscience. AmyP53 targets a fundamental common mechanism in both diseases by blocking the formation of neurotoxic amyloid oligomers, which are responsible for cognitive decline. The drug candidate is administered non-invasively via nasal spray and is the first representative of a new therapeutic class capable of treating both Alzheimer's and Parkinson's. AmyPore's approach is based on over 20 years of neuroscience research by internationally recognized professors Nouara Yahi and Jacques Fantini, who hold the intellectual property rights to AmyP53. The company has received support from the European Commission and other institutions and holds exclusive global development rights for AmyP53 as a drug. AmyPore is positioned as a pioneering biotech innovator targeting a novel therapeutic pathway with a scalable solution for major neurodegenerative diseases.
AmyPore
AmyPore is a biotechnology company founded in 2018 that designs and develops therapeutic peptides to create treatments for neurodegenerative diseases, specifically Alzheimer's and Parkinson's diseases. Their lead product, AmyP53, is a chimeric peptide developed through an innovative strategy combining molecular modeling and artificial intelligence applied to molecular neuroscience. AmyP53 targets a fundamental common mechanism in both diseases by blocking the formation of neurotoxic amyloid oligomers, which are responsible for cognitive decline. The drug candidate is administered non-invasively via nasal spray and is the first representative of a new therapeutic class capable of treating both Alzheimer's and Parkinson's. AmyPore's approach is based on over 20 years of neuroscience research by internationally recognized professors Nouara Yahi and Jacques Fantini, who hold the intellectual property rights to AmyP53. The company has received support from the European Commission and other institutions and holds exclusive global development rights for AmyP53 as a drug. AmyPore is positioned as a pioneering biotech innovator targeting a novel therapeutic pathway with a scalable solution for major neurodegenerative diseases.